Plus, for members only: the next chapter of The Street Sheet is here.
Plus, a biotech with a whopping 75% potential upside...
Plus, a hardware giant whose AI backlog forced a target jump from $29 to $74...
One stock pick from a top-ranked analyst with an implied upside of 100% or more.
Plus, the third-best analyst on Wall Street’s 44% upside call.
Plus, a grid intelligence leader with a record $4.4B backlog.
Plus, a Top 1% analyst weighs in on Wall Street's biggest stock.
Plus, a Top 1% UBS stock picker sees almost 50% upside on this chipmaker, and more.
Plus, the 9th best analyst on Wall Street's favorite AI call, and more.
Plus, the latest ticker from a Wall Street analyst with +186% average returns, a Top 1% analyst's take on Tesla, and more.
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
The market may be missing a protein upgrade that favors eggs.
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
